Clinical implications of T cell exhaustion for cancer immunotherapy
Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
Chimeric antigen receptor (CAR) therapy has had a transformative effect on the treatment of
haematologic malignancies,,,,–, but it has shown limited efficacy against solid tumours. Solid …
haematologic malignancies,,,,–, but it has shown limited efficacy against solid tumours. Solid …
Engineered cellular immunotherapies in cancer and beyond
This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of
hematologic malignancies. Approximately half of patients with refractory large B cell …
hematologic malignancies. Approximately half of patients with refractory large B cell …
The journey of CAR-T therapy in hematological malignancies
J Lu, G Jiang - Molecular cancer, 2022 - Springer
Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive
relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It …
relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It …
[HTML][HTML] Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Cancer immunotherapy has significantly flourished and revolutionized the limited
conventional tumor therapies, on account of its good safety and long-term memory ability …
conventional tumor therapies, on account of its good safety and long-term memory ability …